(Seattle Children's Hospital) A Bispecific PD-L1:CD3 T-cell Engager Potently Kills Intractable Primary And Metastatic Intracranial Tumors

Abstract

Central nervous system (CNS) tumors represent a large unmet medical need. Many pediatric and adult brain cancers and other cancers (e.g., lung, colon, breast) with CNS involvement remain largely intractable despite standard of care and advanced treatment strategies. We engineered a bispecific PD-L1:CD3 T-cell engager (TCE) and discovered promising efficacy in a wide range of pre-clinical intracranial tumor models, including some models with intact blood brain barriers.